Replies to post #47209 on NanoViricides Inc. (NNVC)

[BonelessCat]

You are posting from the same source that has already been debunked.

As I have stated repeatedly and evidenced, The base drug in Alimta IS NOT ALIMTA!!! Alimta is the marketing name for the base drug plus all the buffers and other materials that make it work in humans. Dr. Menon was the lead researcher and principle in the discovery process that allowed the base drug to go from a university project to a marketable drug.

Menon has a Ph.D. in Pharmacology from Harvard. he is also a certified toxicologist. In addition, he is a Doctor of Veterinary Medicine, which makes his contributions invaluable to pre-clinical discovery for effective and safe drug design.

[bloomvest]

As DR F said, Menon Article was Debunked

The same paper seems to have gotten rid of the writer and printed this article later. http://www.cellceutix.com/pdf/Article%20in%20Indus%20Business%20Journal%209-30-09.pdf

The article claimed Dr. Frei did not know Dr. Menon. Just this week Dr. Frei commented about Dr. Menon
http://finance.yahoo.com/news/Cellceutix-Discovers-Drug-prnews-2540244465.html?x=0&.v=1

The data was presented to Cellceutix Scientific Advisor, Emil Frei III, MD, who is Physician-in-Chief emeritus at Harvard University's world renowned Dana-Farber Cancer Institute and Distinguished Professor of Medicine at Harvard Medical School. Dr. Frei was honored by the American Association for Cancer Research with its inaugural lifetime achievement award for revolutionizing chemotherapy and his role in developing the first treatment leading to the complete cure for childhood leukemia. ( http://www.dana-farber.org/abo/news/press/040704.asp ) After reviewing the most recent data on Kevetrin's method of action regarding leukemia, Dr. Frei commented, "The p53 mechanism of Kevetrin as a possible new therapy for leukemia is very exciting and holds significant promise. After Dr. Menon's years of hard work, I am impressed with the progress of this novel compound. I look forward to the commencement of human trials and the realization of Kevetrin's potential as a new therapy for a wide array of cancers."